Clinical trials
Gastrointestinal clinical trials
Below are recruiting gastrointestinal clinical trials, each written for real people, not researchers. We’re tracking 482 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT04363983Recruiting
Study of immune and tumor interactions in digestive cancers
This study looks at how tumors in the digestive system interact with the body’s immune system and the surrounding environment. Results may help improve understanding of these cancers and guide future treatments.
Boulogne-BillancourtAges 18 years+ - NCT04208828Recruiting
IVIG for difficult gastrointestinal auto-immune nerve symptoms
This trial tests intravenous immunoglobulin (IVIG), a donated antibody treatment, for people whose gastrointestinal (GI) “motor” symptoms are not improving with standard care and may be auto-immune related. If you’re eligible, IVIG could help calm the immune system and improve gut movement symptoms.
Louisville, KentuckyAges 12–90 - NCT04662918Recruiting
Test the CAGIB score to predict death in cirrhosis with bleeding
This study checks whether a score called CAGIB can accurately predict the risk of dying during the hospital stay for people with cirrhosis who have sudden bleeding in the digestive tract. It may help doctors identify who needs the most urgent care and monitor outcomes more accurately.
Scranton, PennsylvaniaAges 18 years+ - NCT04838327Recruiting
Study for rare gut cancer types with targeted treatment
This study looks at rare types of gastrointestinal (GI) cancer and may match you to a targeted treatment. It also collects blood and other samples to better understand your cancer and help researchers learn what works.
Aarhus NAges 18 years+ - NCT04902248Recruiting
Compare two procedures for hard-to-stop upper stomach bleeding
This trial studies whether a newer “OTSC” procedure works as well as a standard procedure called angiographic embolization to stop active, hard-to-control upper gastrointestinal bleeding. It may help people whose bleeding continues or comes back even after initial endoscopy treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04933669RecruitingPhase 2
Pre-surgery imatinib for high-risk stomach or gut GIST
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07697248Recruiting
GIST patient registry study
This study is creating a registry to track people with GIST over time. Participating helps researchers learn more about the disease and improve future care.
Wayne, New JerseyAges Any age - NCT04937647Recruiting
Using AI during endoscopy to evaluate stomach and bowel changes
This study looks at how well a computer “AI” system can help doctors spot stomach and bowel abnormalities during endoscopy (camera tests of the gut). If you’re having a gastroscopy or colonoscopy for symptoms or follow-up care, this could improve how findings are recognized.
Portsmouth, HampshireAges 18 years+ - NCT04949282Recruiting
Lutetium-177 treatment for advanced somatostatin-positive tumors
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
Santiago de Compostela, A CoruñaAges 18–100 - NCT05002166Recruiting
Study of children with inflammatory bowel disease risks
This study looks at the typical features and risk factors in children diagnosed with inflammatory bowel disease (IBD). It may help families understand what affects IBD in kids, even if it is not testing a new treatment.
AsyutAges Up to 18 years - NCT05041374Recruiting
Study for adults with digestive or liver problems
This study looks at adults who have known or possible problems in the digestive system or liver. It may help patients by offering structured evaluation and follow-up for their condition.
Bethesda, MarylandAges 18–120 - NCT05176665RecruitingPhase 1/Phase 2
EMB-01 for advanced stomach, bile, liver, and colon cancers
This early-phase trial studies EMB-01 in people with advanced or metastatic gastrointestinal cancers to see how well it works and how safe it is. To join, your tumor’s DNA or protein pattern (especially EGFR or cMET) must match specific lab results, and you must have tried standard treatments.
Houston, TexasAges 18 years+ - NCT05199532Recruiting
Eosinophilic gut condition registry for children
This study builds a registry of children with eosinophilic gastrointestinal (gut) disorders (EGIDs) and also includes children being evaluated for possible EGIDs. It may help doctors better understand these conditions and improve future care.
Chicago, IllinoisAges 1–25 - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Birmingham, AlabamaAges 18 years+ - NCT05219903Recruiting
Study of children with eosinophilic gut disorders
This study looks at children ages 0–18 with eosinophilic gut disorders (EGIDs) to better understand these conditions and how they are managed. It may help doctors improve care by comparing real-world information from patients followed at participating hospitals.
PaviaAges birth–18 years - NCT05252078RecruitingPhase 2
Anlotinib plus an injection after esophageal cancer surgery
This Phase 2 study tests whether anlotinib tablets combined with an injection (TQB2450) can lower the risk of esophageal squamous cell cancer coming back after surgery. It may help by targeting cancer growth signals and blood-vessel formation to reduce recurrence.
Nanchang, JiangxiAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05274854Recruiting
Practice change study for severe unexplained gut symptoms
This study looks at a new approach to care for adults with severe, long-lasting stomach or bowel symptoms when no clear cause has been found. It may help you get more coordinated support through an integrated care clinic.
Woolloongabba, QueenslandAges 18–90 - NCT05385549RecruitingPhase 2
5-Year imatinib after GIST surgery for high-risk patients
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Seoul, SeoulAges 20 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT05465629Recruiting
Viome nutrition program for IBS symptoms
This trial studies whether a Viome nutrition program (based on supplement/formulation instructions) can improve symptoms in people with IBS. You may be asked to follow a specific nutrition plan and tracking steps for the study period.
Bothell, WashingtonAges 25–75 - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75
Hear when a new Gastrointestinal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal?
- Yes. Clin2 currently lists 482 recruiting gastrointestinal studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.